Zobrazeno 1 - 10 of 1 387 pro vyhledávání: '"Velkoska, E."'
1
Akademický článek
Preclinical safety and efficacy of the recombinant CR1 drug product CSL040 in rats and cynomolgus monkeys.
Autor: Ruthsatz T; CSL Behring GmbH, Austria Campus 6, Vienna, Austria., Wymann S; CSL Biologics Research Centre, Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland., Velkoska E; CSL Ltd, Bio21 Institute, Victoria, Australia., Mansour M; CSL Ltd, Bio21 Institute, Victoria, Australia., Schu D; CSL Behring Innovation GmbH, Marburg, Germany., Lichtfuss M; CSL Ltd, Bio21 Institute, Victoria, Australia., Rossato P; CSL Behring Innovation GmbH, Marburg, Germany., FitzPatrick M; CSL Ltd, Bio21 Institute, Victoria, Australia., Hosback S; CSL Ltd, Bio21 Institute, Victoria, Australia., Dyson A; CSL Ltd, Bio21 Institute, Victoria, Australia., Herzog E; CSL Behring LLC, 1020 First Avenue, King of Prussia, PA, USA., Martin K; CSL Ltd, Bio21 Institute, Victoria, Australia., Dietrich B; CSL Behring GmbH, Austria Campus 6, Vienna, Austria., Hardy MP; CSL Ltd, Bio21 Institute, Victoria, Australia. Electronic address: matt.hardy@csl.com.au.
Publikováno v: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2024 Dec 06; Vol. 495, pp. 117191. Date of Electronic Publication: 2024 Dec 06.
Zobrazit plný text záznamu
2
Akademický článek
Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.
Autor: Cooper M; CSL Behring LLC, King of Prussia, Pennsylvania., Cherney DZI; Division of Nephrology, University of Toronto, Toronto, Ontario, Canada., Greene TH; Division of Biostatistics, University of Utah, Salt Lake City, Utah., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; The George Institute for Global Health, Sydney, New South Wales, Australia., Jardine M; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Lewis JB; Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee., Wong MG; Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Baquero E; CSL Behring LLC, King of Prussia, Pennsylvania., Heise M; CSL Behring LLC, King of Prussia, Pennsylvania., Jochems J; CSL Behring LLC, King of Prussia, Pennsylvania., Lanchoney D; CSL Behring LLC, King of Prussia, Pennsylvania., Liss C; CSL Behring LLC, King of Prussia, Pennsylvania., Reiser D; CSL Behring LLC, King of Prussia, Pennsylvania., Scotney P; CSL Ltd., Bio21 Institute, Melbourne, Victoria, Australia., Velkoska E; CSL Ltd., Bio21 Institute, Melbourne, Victoria, Australia., Dwyer JP; Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.
Publikováno v: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2024 Nov 01; Vol. 35 (11), pp. 1546-1557. Date of Electronic Publication: 2024 Aug 16.
Zobrazit plný text záznamu
3
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Autor: Chertow GM; Stanford University, Palo Alto, CA, USA. gchertow@stanford.edu., Chang AM; CSL Behring, King of Prussia, PA, USA., Felker GM; Duke University, Durham, NC, USA., Heise M; CSL Behring, King of Prussia, PA, USA., Velkoska E; CSL Limited, Melbourne, Victoria, Australia., Fellström B; Uppsala University, Uppsala, Sweden., Charytan DM; New York University, New York City, NY, USA., Clementi R; CSL Behring, King of Prussia, PA, USA., Gibson CM; Harvard Medical School, Boston, MA, USA., Goodman SG; University of Toronto and University of Alberta, Edmonton, Alberta, Canada., Jardine M; University of Sydney, Sydney, New South Wales, Australia., Levin A; University of British Columbia, Vancouver, British Columbia, Canada., Lokhnygina Y; Duke University, Durham, NC, USA., Mears J; CSL Behring, King of Prussia, PA, USA., Mehran R; Mt Sinai Hospital, New York City, NY, USA., Stenvinkel P; Karolinska Institute, Solna, Sweden., Wang AY; Hong Kong University, Hong Kong, China., Wheeler DC; University College London, London, UK., Zoccali C; Ospedali Riuniti Reggio Calabria, Reggio di Calabria, Italy., Ridker PM; Harvard Medical School, Boston, MA, USA., Mahaffey KW; Stanford University, Palo Alto, CA, USA., Tricoci P; CSL Behring, King of Prussia, PA, USA., Wolf M; Duke University, Durham, NC, USA.
Publikováno v: Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2373.
Zobrazit plný text záznamu
4
Akademický článek
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Autor: Chertow GM; Stanford University, Palo Alto, CA, USA. gchertow@stanford.edu., Chang AM; CSL Behring, King of Prussia, PA, USA., Felker GM; Duke University, Durham, NC, USA., Heise M; CSL Behring, King of Prussia, PA, USA., Velkoska E; CSL Limited, Melbourne, Victoria, Australia., Fellström B; Uppsala University, Uppsala, Sweden., Charytan DM; New York University, New York City, NY, USA., Clementi R; CSL Behring, King of Prussia, PA, USA., Gibson CM; Harvard Medical School, Boston, MA, USA., Goodman SG; University of Toronto and University of Alberta, Edmonton, Alberta, Canada., Jardine M; University of Sydney, Sydney, New South Wales, Australia., Levin A; University of British Columbia, Vancouver, British Columbia, Canada., Lokhnygina Y; Duke University, Durham, NC, USA., Mears J; CSL Behring, King of Prussia, PA, USA., Mehran R; Mt Sinai Hospital, New York City, NY, USA., Stenvinkel P; Karolinska Institute, Solna, Sweden., Wang AY; Hong Kong University, Hong Kong, China., Wheeler DC; University College London, London, UK., Zoccali C; Ospedali Riuniti Reggio Calabria, Reggio di Calabria, Italy., Ridker PM; Harvard Medical School, Boston, MA, USA., Mahaffey KW; Stanford University, Palo Alto, CA, USA., Tricoci P; CSL Behring, King of Prussia, PA, USA., Wolf M; Duke University, Durham, NC, USA.
Publikováno v: Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2328-2336. Date of Electronic Publication: 2024 May 25.
Zobrazit plný text záznamu
5
Report
CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.
Autor: Kingwell BA; CSL Ltd Bio21 Institute Melbourne Victoria Australia., Duffy D; CSL Behring King of Prussia PA USA., Clementi R; CSL Behring King of Prussia PA USA., Velkoska E; CSL Ltd Bio21 Institute Melbourne Victoria Australia., Feaster J; CSL Behring King of Prussia PA USA., Gibson CM; PERFUSE Study Group Boston and Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA.
Publikováno v: Journal of the American Heart Association [J Am Heart Assoc] 2024 May 07; Vol. 13 (9), pp. e033541. Date of Electronic Publication: 2024 May 03.
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat
Autor: Velkoska, E., Warner, F.J., Cole, T.J., Smith, I., Morris, M.J.
Publikováno v: In Nutrition, Metabolism and Cardiovascular Diseases January 2010 20(1):49-55
Zobrazit plný text záznamu
8
Akademický článek
CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction.
Autor: Didichenko SA; CSL Behring, Bern, Switzerland (S.A.D., A.V.N.)., Velkoska E; CSL Ltd, Bio21 Institute, Melbourne, Australia (E.V., B.A.K.)., Navdaev AV; CSL Behring, Bern, Switzerland (S.A.D., A.V.N.)., Greene BH; CSL Behring, Marburg, Germany (B.H.G.)., Lorkowski SW; Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, OH (S.W.L., J.D.S.)., Duffy D; CSL Behring, King of Prussia, PA (D.D., S.J.M., S.D.W.)., Mears SJ; CSL Behring, King of Prussia, PA (D.D., S.J.M., S.D.W.)., Wright SD; CSL Behring, King of Prussia, PA (D.D., S.J.M., S.D.W.)., Gibson CM; PERFUSE Study Group, Boston and Beth Israel Deaconess Medical Center, Harvard Medical School, MA (C.M.G.)., Smith JD; Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, OH (S.W.L., J.D.S.)., Kingwell BA; CSL Ltd, Bio21 Institute, Melbourne, Australia (E.V., B.A.K.).
Publikováno v: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2023 Jun; Vol. 43 (6), pp. 855-869. Date of Electronic Publication: 2023 Mar 30.
Zobrazit plný text záznamu
9
Akademický článek
A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assay.
Autor: Davis R; CSL Innovation Pty Ltd, Melbourne, Australia. Electronic address: roslyn.davis@csl.com.au., Velkoska E; CSL Innovation Pty Ltd, Melbourne, Australia., McCallum H; CSL Innovation Pty Ltd, Melbourne, Australia., Majcen B; CSL Innovation Pty Ltd, Melbourne, Australia., Gille A; CSL Behring, Pasadena, USA., Kingwell BA; CSL Innovation Pty Ltd, Melbourne, Australia., Martin K; CSL Innovation Pty Ltd, Melbourne, Australia.
Publikováno v: Journal of immunological methods [J Immunol Methods] 2023 Feb; Vol. 513, pp. 113411. Date of Electronic Publication: 2022 Dec 29.
Zobrazit plný text záznamu
10
Akademický článek
Undernutrition during suckling in rats elevates plasma adiponectin and its receptor in skeletal muscle regardless of diet composition: a protective effect?
Autor: Prior, L. J.1, Velkoska, E.1, Watts, R.2, Cameron-Smith, D.2, Morris, M. J.1,3 m.morris@unsw.edu.au
Publikováno v: International Journal of Obesity. Oct2008, Vol. 32 Issue 10, p1585-1594. 10p. 3 Charts, 5 Graphs.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje